Fine-tuning signal strength in CD5 CAR-NK cells for targeted T cell cancer therapy.

ABSTRACT:

Introduction

T cell hematological malignancies are aggressive blood cancers that remain challenging despite various treatments. Current chimeric antigen receptor (CAR)-T and natural killer (NK) therapies show potential but struggle with nonselective elimination during tumor targeting. Since CAR signal strength is determined by the single-chain variable fragment (scFv) and CAR expression levels, fine-tuning these parameters enables selective recognition of malignant cells while preserving normal cells. Here, we aimed to develop optimized CD5 CAR-NK cells (OptiCAR-NK) to achieve potent anti-tumor activity with minimized off-tumor toxicity.

Methods

We engineered CD5 CAR-NK cells with different scFv and CAR expression levels. CAR expression was modulated by single-cell isolation

SUBMITTER: Jo S 

PROVIDER: S-EPMC12491253 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature